Novartis' ($NVS) Alcon received CE mark approval to sell its AcrySof IQ PanOptix trifocal intraocular lens in Europe. The implantable lens corrects near, intermediate and distance vision in cataract patients.
The device is indicated for "adult patients with and without presbyopia undergoing cataract surgery who desire near, intermediate and distance vision with increased spectacle independence," according to an Alcon release.
Alcon says that more than three million cataract surgeries are performed annually in Europe. Without IOLs, the patients often require glasses or contact lenses following the surgery.
"Today's patients undergoing cataract surgery are more likely to seek vision correction options to address various lifestyle tasks such as reading books, using electronic tablets, working on computers and performing outdoor activities without the need for glasses or contact lenses," said ophthalmologist Dr. Richard Packard, director of Arnott Eye Associates in London, in a statement. "The AcrySof IQ PanOptix trifocal IOL is an important option that should provide these patients with a full range of vision and thus significantly reduced dependence on glasses."
In April, Alcon received FDA approval for its implantable AcrySof IQ ReSTOR +2.5 Diopter intraocular lens, enabling vision correction at all distances in eye care patients with or without presbyopia who undergo cataract surgery.
Alcon is still awaiting word from the FDA about the AcrySof IQ ReSTOR Multifocal Toric Intraocular Lens. It is for patients suffering from both astigmatism and presbyopia. If approved, it would be first multifocal IOL in the U.S. that corrects corneal astigmatism and provides near, intermediate and distance vision, the FDA previously told FierceMedicalDevices.
- read the release